论文部分内容阅读
目的观察卡维地洛治疗老年充血性心力衰竭的临床疗效及安全性分析。方法 2010年1月至2012年1月期间,我院诊治的72例老年充血性心力衰竭患者,随机将其分为对照组(常规治疗)和观察组(对照组治疗基础上,加用卡维地洛),每组各36例,治疗4个月,对两组的临床疗效,进行观察和比较。结果 36例观察组患者中,18例显效,14例有效,4例无效;36例对照组患者中,12例显效,13例有效,11例无效。与对照组相比(69.4%),观察组总有效率明显升高(88.9%),P<0.05;治疗后,两组心功能都有所改善。与对照组相比(29.5±4.0),观察组左室射血分数明显增高(46.0±3.5),(t=2.35,P<0.05);治疗期间,两组患者没有出现严重的不良反应,实验室检查指标也没有明显改变。结论对于老年充血性心力衰竭患者,常规治疗基础上,加用卡维地洛,明显改善了患者的心功能,显著提高了临床疗效,并且不良反应相对较少,值得临床推广。
Objective To observe the clinical efficacy and safety of carvedilol in elderly patients with congestive heart failure. Methods From January 2010 to January 2012, 72 elderly patients with congestive heart failure diagnosed and treated in our hospital were randomly divided into control group (conventional treatment) and observation group (control group based on the treatment with carved Dex), 36 cases in each group, for 4 months, the clinical efficacy of the two groups were observed and compared. Results Of the 36 patients in the observation group, 18 were markedly effective, 14 were effective and 4 were ineffective. Out of the 36 patients in the control group, 12 were markedly effective, 13 were effective and 11 were ineffective. Compared with the control group (69.4%), the total effective rate in the observation group was significantly increased (88.9%), P <0.05; after treatment, both groups had an improvement in cardiac function. Compared with the control group (29.5 ± 4.0), the left ventricular ejection fraction was significantly higher in the observation group (46.0 ± 3.5), (t = 2.35, P <0.05). During the treatment period, no serious side effects occurred in both groups. Room examination index did not change significantly. Conclusion For elderly patients with congestive heart failure, conventional treatment based on the addition of carvedilol significantly improved the patient’s cardiac function, significantly improved the clinical efficacy and adverse reactions are relatively small, worthy of clinical promotion.